A novel combination treatment against melanoma with  NRAS  mutation and therapy resistance | Zendy

Yu Yanlin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A novel combination treatment against melanoma with NRAS mutation and therapy resistance

Author(s) -

Yu Yanlin

Publication year - 2018

Publication title -

embo molecular medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.923

H-Index - 107

eISSN - 1757-4684

pISSN - 1757-4676

DOI - 10.15252/emmm.201708573

Subject(s) - neuroblastoma ras viral oncogene homolog , cancer , melanoma , cancer research , targeted therapy , mutant , mutation , medicine , biology , gene , genetics , kras , colorectal cancer

Targeted cancer therapies have shown some progress in treating BRAF ‐mutant melanoma, but not against NRAS ‐mutant and treatment‐resistant melanoma. In this issue of EMBO Molecular Medicine , Echevarría‐Vargas et al ([Echevarría‐Vargas IM, 2018]) report that cotargeting BET and MEK pathways efficiently kills immune therapy‐resistant and NRAS ‐mutant melanoma tumor cells.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research